公开(公告)号：US11344538B2

公开(公告)日：2022-05-31

申请号：US16796364

申请日：2020-02-20

申请人： Lenz Therapeutics, Inc.

发明人： Gerald Horn

IPC分类号： A61K31/439 ,  A61K47/10 ,  A61K47/40 ,  A61P27/10 ,  A61K47/38 ,  A61K31/498 ,  A61K31/131 ,  A61K47/26

摘要： The invention provides methods for the treatment of myopia. The compositions preferably comprise aceclidine. The compositions optionally contain a surfactant, a viscosity agent, a polyol and/or a selective α-2 adrenergic receptor agonist.

公开(公告)号：US20220135556A1

公开(公告)日：2022-05-05

申请号：US17574884

申请日：2022-01-13

申请人： Evrys Bio, LLC

发明人： Stacy Remiszewski ,  Emre Koyuncu ,  Qun Sun ,  Lillian Chiang

IPC分类号： C07D417/14 ,  A61K31/427 ,  C07D417/04 ,  C07D491/052 ,  C07D417/06 ,  C07D417/10 ,  A61K45/06 ,  A61K31/436 ,  A61K31/4725 ,  A61K31/498 ,  A61K31/5377 ,  A61K31/506 ,  A61K31/4709

摘要： Novel compounds useful for treating and/or preventing HCMV infections are provided.

公开(公告)号：US20220135544A1

公开(公告)日：2022-05-05

申请号：US17451601

申请日：2021-10-20

申请人： ASTEX THERAPEUTICS LTD

发明人： Gordon SAXTY ,  Christopher William Murray ,  Valerio Berdini ,  Gilbert Ebai Besong ,  Christopher Charles Frederick Hamlett ,  Christopher Norbert Johnson ,  Steven John Woodhead ,  Michael Reader ,  David Charles Rees ,  Laurence Anne Mevellec ,  Patrick René Angibaud ,  Eddy Jean Edgard Freyne ,  Tom Cornelis Hortense Govaerts ,  Johan Erwin Edmond Weerts ,  Timothy Pietro Suren Perera ,  Ronaldus Arnodus Hendrika Joseph Gilissen ,  Berthold Wroblowski ,  Jean Fernand Armand Lacrampe ,  Alexandra Papanikos ,  Olivier Alexis Georges Querolle ,  Elisabeth Thérèse Jeanne Pasquier ,  Isabelle Noëlle Constance Pilatte ,  Pascal Ghislain André Bonnet ,  Werner Constant Johan Embrechts ,  Rhalid Akkari ,  Lieven Meerpoel

IPC分类号： C07D403/04 ,  C07D403/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D487/08 ,  A61K31/498 ,  A61K31/5377 ,  A61K45/06 ,  C07D491/113 ,  C07D401/14 ,  C07F9/6524

摘要： The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

公开(公告)号：US20220105103A1

公开(公告)日：2022-04-07

申请号：US17494713

申请日：2021-10-05

申请人： Somerset Therapeutics, LLC

发明人： Mandar V. Shah ,  Ilango Subramanian ,  Veerappan Subramanian ,  Aman Trehan

IPC分类号： A61K31/542 ,  A61K31/498 ,  A61K47/18 ,  A61K47/10 ,  A61K47/02 ,  A61K9/00 ,  A61K9/08

摘要： Disclosed herein are safe pharmacologically acceptable and ophthalmologically suitable compositions and methods of their use in treating ophthalmic diseases or related conditions. Disclosed are compositions comprising effective amounts of carbonic anhydrase inhibitor(s) and alpha-2-adrenergic agonist(s) and an effective amount of a penetration enhancement component comprising one or more penetration enhancer compound(s)/molecule(s), e.g., benzalkonium chloride, which detectably or significantly increases the penetration of API(s) of the composition. In aspects, the invention provides compositions comprising a brinzolamide compound in an amount of about 0.1 wt. %-10 wt. % of the composition, a brimonidine compound, e.g., brimonidine tartrate, in an amount of about 0.01 wt. %-0.5 wt. % of the composition, one or more borate-polyol complexes in an amount of about 0.5 wt. %-6 wt. % of the composition, and a penetration enhancement component comprising benzalkonium chloride, in, for example, an amount of about 0.005-0.02 wt. % of the composition.

公开(公告)号：US20220105100A1

公开(公告)日：2022-04-07

申请号：US17494635

申请日：2021-10-05

申请人： Somerset Therapeutics, LLC

发明人： Mandar V. Shah ,  Ilango Subramanian ,  Veerappan Subramanian ,  Aman Trehan

IPC分类号： A61K31/542 ,  A61K31/498 ,  A61K47/18 ,  A61K47/10 ,  A61K47/02 ,  A61K9/00 ,  A61K9/08

摘要： Disclosed herein are safe pharmacologically acceptable and ophthalmologically suitable compositions and methods of their use in treating ophthalmic diseases or related conditions. Disclosed are compositions comprising effective amounts of carbonic anhydrase inhibitor(s) and alpha-2-adrenergic agonist(s) and an effective amount of a penetration enhancement component comprising one or more penetration enhancer compound(s)/molecule(s), e.g., benzalkonium chloride, which detectably or significantly increases the penetration of API(s) of the composition. In aspects, the invention provides compositions comprising a brinzolamide compound in an amount of about 0.1 wt. %-10 wt. % of the composition, a brimonidine compound, e.g., brimonidine tartrate, in an amount of about 0.01 wt. %-0.5 wt. % of the composition, one or more borate-polyol complexes in an amount of about 0.5 wt. %-6 wt. % of the composition, and a penetration enhancement component comprising benzalkonium chloride, in, for example, an amount of about 0.005-0.02 wt. % of the composition.

公开(公告)号：US20220096513A1

公开(公告)日：2022-03-31

申请号：US16498897

申请日：2018-03-30

申请人： THE BROAD INSTITUTE, INC. ,  DANA-FARBER CANCER INSTITUTE, INC.

发明人： STEVEN M. CORSELLO ,  TODD R. GOLUB ,  ERIC STEFAN ,  ROBERT HILGRAF

IPC分类号： A61K31/7064 ,  A61K31/4439 ,  A61K31/498

摘要： The present invention includes CSNK1A1 inhibitors that are useful in treating or preventing a cancer in a subject. In certain embodiments, the cancer comprises a hematological cancer, such as but not limited to acute myeloid leukemia (AML) and/or MDS (myelodysplastic syndrome, including 5q-MDS). In other embodiments, the cancer comprises colon cancer.

公开(公告)号：US11285154B2

公开(公告)日：2022-03-29

申请号：US15940802

申请日：2018-03-29

申请人： United States Government as Represented by The Department of Veterans Affairs

发明人： Amyn Aziz Habib

IPC分类号： A61K31/517 ,  A61K45/06 ,  A61K31/454 ,  A61P35/00 ,  A61K31/502 ,  A61K31/4985 ,  A61K31/4439 ,  A61K31/17 ,  A61K31/416 ,  A61K31/277 ,  A61K31/498 ,  A61K31/4178 ,  A61K31/713 ,  C07K16/24 ,  A61K38/17 ,  A61K31/573

摘要： Provided herein are methods and pharmaceutical compositions for treating cancer, in a patient in need thereof, said method comprising administering to said patient an effective amount of an EGFR inhibitor and a TNF inhibitor.

公开(公告)号：US11253633B2

公开(公告)日：2022-02-22

申请号：US15521779

申请日：2015-10-27

申请人： I.CERAM

发明人： François Bertin ,  Eric Denes ,  Fabrice Fiorenza ,  Franck Sturtz ,  Daniel Setton

IPC分类号： A61L27/54 ,  A61L27/56 ,  A61K9/00 ,  A61K31/498 ,  A61L27/10 ,  A61L27/18

摘要： The invention relates to a composition for the release of an active ingredient, comprising a porous matrix, a filled carrier in the matrix and the active ingredient in the carrier. The invention is suitable for the treatment of bone cancers.

公开(公告)号：US20220031739A1

公开(公告)日：2022-02-03

申请号：US17389556

申请日：2021-07-30

申请人： Eye Therapies LLC

发明人： Gerald Horn

IPC分类号： A61K33/30 ,  A61K31/4168 ,  A61K31/137 ,  A61K31/498 ,  A61K31/155 ,  A61K31/198 ,  A61K31/4164 ,  A61K31/4178 ,  A61K47/32 ,  A61K47/44 ,  A61K47/38 ,  A61K47/26 ,  A61K47/18

摘要： The present invention is directed to anti-viral compositions comprising zinc, optionally, an alpha-adrenergic receptor agonist, one or more nonionic surfactants and one or more viscosity enhancers. The present invention is further directed to methods of treating viral infections comprising administering compositions of the present invention to a subject in need thereof.

公开(公告)号：US11224596B2

公开(公告)日：2022-01-18

申请号：US16490677

申请日：2018-02-28

申请人： Janssen Sciences Ireland Unlimited Company

发明人： Koenraad Jozef Lodewijk Marcel Andries ,  Anil Koul ,  Maria Cristina Villellas Arilla

IPC分类号： A61K31/4965 ,  A61P31/06 ,  A61K31/438 ,  A61K31/4545 ,  A61K31/47 ,  A61K31/498

摘要： The present invention relates to novel combinations, which are useful in the treatment of tuberculosis.